News

Eli Lilly's recent GLP-2 deal with Hanmi Pharm is another step in the drugmaker’s quest to grow its GLP franchise beyond weight loss and deepen its push into gastrointestinal disease.

Novo Nordisk (NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wego

Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation.

Led by top holdings like Popular, East West Bancorp and Zions, KRE ETF is in buy range as the financial ETF flashes signs of strength.

NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.

PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.

Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.

Hyderabad-based Electronics Mart India is looking to diversify away from the technology hub as concerns grow that potential AI-triggered ‌job losses could hurt consumer spending, a top executive said. The retailer gets ‌about 60% of its revenue from Hyderabad, which hosts offices of global companies such as JPMorgan Chase ​and Eli Lilly, and Indian IT majors Wipro and Infosys. Around a fifth of its stores in Hyderabad are located in neighbourhoods where the majority of the residents are software employees.

Eli Lilly (NYSE:LLY) reported Phase 1 data for AJ1-11095, a first-in-class type II JAK2 inhibitor, in myelofibrosis patients. The AJX-101 study focused on individuals whose disease continued after prior type I JAK2 inhibitor treatment. Early results showed encouraging safety findings and clinical activity in this difficult to treat group. Eli Lilly is widely associated with its obesity drug portfolio, but the AJ1-11095 update highlights a broader pipeline that includes hematology and...

Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels.

The National Bureau of Economic Research paper's lead author hopes putting a dollar value on the benefits of GLP-1s will lead to better access

With a profit margin of 34.99% and net income of $20.64 billion (FY25), Eli Lilly and Company (NYSE:LLY) ranks among the most profitable blue chip stocks to buy according to hedge funds. Meanwhile, analysts see 9.20% upside for the stock. That outlook comes during a particularly active stretch of regulatory and clinical news for Lilly’s […]

We recently published Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the stocks discussed by Jim Cramer. Healthcare and pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Jim Cramer’s favorite stocks. Throughout 2025, the CNBC TV regularly praised the firm […]

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -2.41% move from the preceding trading day.

While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.

Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.

Eli Lilly (NYSE:LLY) has invested in Abridge, an AI-focused clinician documentation company. The partnership connects Lilly to Abridge's clinical conversation data platform, used across hundreds of health systems. The deal is aimed at using AI tools to speed up drug development, clinical trial enrollment, and evidence-based research. Eli Lilly is widely followed for its pharmaceutical portfolio, including obesity treatments and other therapies that have driven much of the recent discussion...

Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out.

With the massive SpaceX debut hogging the headlines, some retail investors may have allowed more prosaic names to slip from their minds. Pharma stock Eli Lilly is trading in a buy zone as institutional investors load up. Eli Lilly is committed to innovation and reinvests 20%-25% of its sales back into developing new treatments.

The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

Eli Lilly and Company (NYSE:LLY) is one of the 7 Best Compounder Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) plans to stop providing 340B discounted drug pricing to certain hospitals that have not complied with claims data reporting requirements introduced on February 1, Fierce Healthcare’s Dave Muoio reported. The move has drawn opposition […]

Eli Lilly (NYSE:LLY) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the GLP-1 mania. But here’s what you should actually be watching. The Hot Ticker Is a Two-Drug Bet at a Trillion-Dollar Price Strip away the ... Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy

Eli Lilly and Company (NYSE:LLY) rose around 12% in May 2026, primarily driven by strong FQ1 2026 earnings beat and FDA approval for Foundayo and expansion of insurance coverage of obesity treatment. With 132 hedge funds holding the stock as of Q1 2026, Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to […]

(Updates with Eli Lilly's response to a request for comment from MT Newswires.) Some employers in

There are already lengthy patient waitlists for the medication on digital health platforms.

New cancer therapies may help fund dividend growth.

The company is working with Nvidia to build a foundation model for clinical conversations, and it scored a strategic investment from drugmaker Eli Lilly, Abridge announced during a sweeping keynote Thursday.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy, according to analysts. On June 7, Eli Lilly and Company (NYSE:LLY) announced top-line results for Foundayo (orforglipron), the only oral GLP-1 that can be taken without food or water restrictions. Clinical trial results showed that women with obesity and who were […]